Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-DXd versus T-DM1 in high-risk HER2-positive primary breast cancer with residual invasive disease after neoadjuvant therapy
2020-003982-20Phase 3Active
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Oct 2020
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in breast cancer comparing trastuzumab deruxtecan with Kadcyla (2 arms). Primary endpoint: Invasive disease-free survival. Started Oct 2020; status: active.
02
Drugs
trastuzumab deruxtecantrastuzumab emtansine
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2020-003982-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003982-20.